Phase 3 NEJM data show oveporexton improves wakefulness, reduces cataplexy, and boosts quality of life in narcolepsy type 1, with manageable adverse effects.
|Articles|March 12, 2012
Sleep Disorders Quiz
Author(s)Psychiatric Times Editors
Listen
0:00 / 0:00
Can you name an important part of good sleep hygiene? The use of which short-acting sedative-hypnotics to treat sleep disturbances in patients is associated with Alzheimer disease? These questions and more.
Advertisement
Can you name an important part of good sleep hygiene? The use of which short-acting sedative-hypnotics to treat sleep disturbances in patients is associated with Alzheimer disease? These questions and more.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Treating PTSD Among Veterans at Risk for Suicide
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
Podcast: Not Always Panic. A Cardiologist and Psychiatrist on Reading a Racing Heart
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5